Peripheral arterial disease (PAD) affects over 230 million people globally, and its most severe manifestation — critical limb ischemia (CLI) — carries a prognosis that surgeons dread: without revascularization, roughly one in four CLI patients lose a limb within a year. The tragedy is that up to 40% of CLI patients have disease anatomy that makes conventional bypass or endovascular revascularization technically impossible. For these patients, mesenchymal stromal cell therapy is no longer an academic curiosity — it is an active area of translational urgency, and 2026 has delivered substantial mechanistic and clinical progress that pushes the field well beyond earlier proof-of-concept work.
The Oxidative Stress Barrier: Why Naive MSCs Fail in CLI
Standard MSC transplantation into ischemic limb muscle faces a fundamental problem: the ROS-rich microenvironment of CLI kills transplanted cells before they can secrete enough paracrine factors to stimulate vascular regrowth. Clinically, this explains why cell therapy trials in CLI have shown inconsistent efficacy despite consistent safety — the cells simply do not survive long enough.
A 2026 study in Molecular Therapy by Shin EJ et al. confronted this obstacle at its genetic root using CRISPR-Cas9. The team targeted Kelch-like ECH-associated protein 1 (KEAP1) — the cytoplasmic repressor that normally keeps the NRF2 antioxidant transcription factor in check. Knockout of KEAP1 in human bone marrow-derived MSCs constitutively activated the NRF2 pathway, reprogramming the cells’ entire redox regulatory network. Edited MSCs showed reduced intracellular ROS accumulation, upregulated HGF, VEGF, and IL-6 paracrine gene expression, and markedly enhanced survival under hypoxia-mimetic conditions in vitro.
In a murine CLTI model, KEAP1-edited MSCs delivered intramuscularly achieved significantly better engraftment than unmodified MSCs, with superior tissue perfusion (laser Doppler imaging) and arteriogenesis (CD31+ vessel density). The approach uses non-viral CRISPR editing — no integration cassette — which makes it potentially amenable to clinical-grade manufacturing. More broadly, this strategy is applicable to any MSC application where ischemia/reperfusion damages transplanted cells: myocardial infarction, stroke, and diabetic complications are all candidate indications for NRF2-primed MSCs.
hiPSC-Derived MSCs Overcome the Autologous Quality Problem in Diabetic CLI
Diabetic CLI patients represent the single largest subgroup in limb salvage clinics, yet they are also the patients whose own bone marrow produces the lowest quality MSCs. Hyperglycemia impairs MSC proliferative capacity, paracrine output, and immunomodulatory function — the exact properties that make MSCs therapeutic. A February 2026 paper in Bioengineering & Translational Medicine (Basu R et al.) addressed this population mismatch by generating MSCs from human induced pluripotent stem cells (hiPSC-MSCs), which are not affected by the donor’s metabolic status.
In a streptozotocin-induced diabetic CLTI model, hiPSC-MSCs injected intramuscularly produced multi-lineage improvements: muscle regeneration markers embryonic myosin heavy chain 3 (p < 0.01) and myoblast determination protein 1 (p = 0.03) were upregulated, VEGF-A expression increased at 7 days (p = 0.04), and the oxidative stress marker p47phox decreased at 30 days (p = 0.02). On the immunological axis, Foxp3 (Treg marker, p = 0.01 at 7 days) and CD206 (M2 macrophage marker, p = 0.04 at 7 days and p = 0.02 at 30 days) were both significantly elevated, suggesting that hiPSC-MSCs drive macrophage polarization from pro-inflammatory M1 to reparative M2 — a cascade that orchestrates both angiogenesis and muscle fiber regeneration.
hiPSC-MSCs have a key manufacturing advantage: they can be expanded from a single master cell bank under cGMP conditions, with lot-to-lot consistency that autologous harvests cannot match. For the CLI population, where many patients are elderly, diabetic, or renally impaired, the ability to manufacture a standardized product without harvesting bone marrow or adipose tissue under general anesthesia is a practical advance.
Combining Two Complementary Cell Populations for Vascular Integration
One of the most innovative 2026 contributions comes from Kim DY et al. in npj Regenerative Medicine (January 2026), who tested whether combining two adipose-derived progenitor populations — vascular multipotent stem cells (VMSCs) and adipose-derived stem cells (ADSCs) — would achieve superior vascular repair through complementary mechanisms.
Phenotypic characterization revealed that VMSCs express endothelial markers (CD31, VE-cadherin, CD141) and form capillary-like tubes in Matrigel, while ADSCs express perivascular markers (alpha-SMA, Transgelin) and function as mural support cells. Co-culture of VMSCs with ADSCs produced branched, stable tubular networks — something neither population could achieve alone. In a murine CLI model, combined intramuscular VMSC + ADSC transplantation significantly reduced limb necrosis and promoted both arteriogenesis (large-vessel formation) and angiogenesis (capillary sprouting). Histologically, transplanted cells physically integrated into host vascular structures, forming hybrid human-mouse vessels.
This finding — that transplanted cells directly participate in vessel wall construction, not just paracrine signaling — is mechanistically significant. It suggests that a two-component cell product mimicking the vessel wall architecture (endothelium + pericyte) may produce more durable vascular repair than any single-cell therapy. The approach is autologous (both populations derived from the same lipoaspirate), simplifying regulatory pathfinding.
Exosomal miR-21-5p: A Defined Therapeutic for Therapeutic Angiogenesis
For clinicians and regulators seeking a cell-free, defined product, hUCB-MSC-derived exosomes represent a compelling alternative. A 2026 study in Current Stem Cell Research and Therapy (Du L et al.) demonstrated that exosomal miR-21-5p is the key cargo driving endothelial tip cell activation: exosome treatment enhanced tip cell proliferation (EdU staining), migration (Transwell), and viability (CCK-8), while reducing apoptosis (flow cytometry). The mechanism was mapped to miR-21-5p-mediated downregulation of TGF-beta1 — the angiogenic effect was fully reversed by exogenous TGF-beta1 supplementation, confirming target specificity.
For PAD therapy, exosomes offer several advantages over living cell products: they are shelf-stable, do not require cold-chain viability preservation, are non-proliferative (no tumorigenicity concern), and can be manufactured under defined conditions from a master cell bank. The miR-21-5p/TGF-beta1 axis identified here provides a specific mechanistic target for potency assay development — a critical need for regulatory submission of any exosome-based vascular product.
Clinical Landscape: Phase II and Phase IV Trials for PAD/CLI
The clinical pipeline for MSC/progenitor cell therapy in CLI includes several active or recently completed trials:
- NCT05854615 (Phase 4, RECRUITING): Stempeucel (Stempeutics, India) — allogeneic bone marrow MSC for CLI due to Buerger’s disease. Stempeucel has received conditional approval in India, making this the most clinically advanced MSC product for PAD.
- NCT05854641 (Phase 4, RECRUITING): Stempeucel for CLI due to atherosclerotic peripheral arterial disease — a broader PAD population.
- NCT02805023 (Phase 1/2, ACTIVE_NOT_RECRUITING): BGC101 (BioGenCell, Israel) — autologous enriched endothelial progenitor cells (EnEPC) from patient’s own blood for CLI.
- NCT06813027 (Phase 1, ACTIVE_NOT_RECRUITING): Allogeneic umbilical cord MSC extracellular secretomes (EVs) — safety and feasibility study for multiple indications including PAD.
- NCT06087848 (RECRUITING): StromaForte expanded adipose MSC for cardiovascular outcomes including peripheral vascular disease.
Beyond MSC trials, the LEGenD-1 Phase II trial (NCT04267640) of AMG0001 — intramuscular plasmid HGF gene therapy — delivered compelling results for CLI wound healing. In 75 patients with neuroischemic ulcers and moderate ischemia (mean toe pressure 46.1 mmHg), HGF gene therapy significantly shortened time to complete ulcer healing compared with placebo (84 vs. 280 days, p = 0.007), with 77.6% healed at 12 months vs. 46.2% for placebo (p = 0.010). This establishes an important benchmark for the next generation of cell-based approaches to the same target population.
Systematic Review: 2026 Clinical Evidence Synthesis
A comprehensive narrative review in Tissue Cell (Ribeiro M, 2026) synthesized the clinical evidence across all major cell platforms for PAD and CLI — bone marrow MSCs, adipose MSCs, umbilical cord cells, fetal progenitor cells, and iPSC-derived products. The review’s main conclusions for practitioners:
- Safety profiles are consistently favorable — no trial has reported serious treatment-related adverse events at therapeutic doses
- Efficacy remains heterogeneous across trials: some show significant improvements in ABI, pain-free walking distance, and wound healing; others show no statistically significant functional benefit
- The dominant mechanism is now established: paracrine signaling and immunomodulation, not direct cellular engraftment or differentiation into endothelial cells
- Key barriers to clinical adoption are not biological but structural: non-standardized manufacturing, lack of validated potency assays, fragmented regulatory requirements across jurisdictions, and cost-effectiveness relative to conventional limb salvage
The review identifies three innovations most likely to catalyze the next clinical advances: biomaterial-assisted delivery (hydrogels that improve cell retention in ischemic muscle beyond 48 hours), exosome-based products that eliminate cold-chain and viability barriers, and precision patient stratification biomarkers that identify responders vs. non-responders before treatment.
Where Cell Therapy for PAD Stands at Mid-2026
Five distinct therapeutic modalities are now generating clinical and mechanistic data in PAD/CLI:
- CRISPR-edited MSCs (KEAP1-NRF2): engineering cells to survive the hostile ischemic microenvironment
- hiPSC-derived MSCs: scalable, quality-controlled cells for diabetic patients whose autologous marrow is compromised
- Combinatorial VMSC + ADSC: two-component cell therapy that mimics native vessel wall architecture
- Exosome-based miR-21-5p therapy: defined, shelf-stable paracrine product for therapeutic angiogenesis
- Allogeneic MSC products (Stempeucel): Phase 4 active in Buerger’s and atherosclerotic CLI
The central question has shifted from “do MSCs work in PAD?” to “which formulation, at what dose, in which patients, and at what stage of disease?” — an inflection point that signals maturation from proof-of-concept to clinical optimization. For the 40% of CLI patients who cannot undergo conventional revascularization, the convergence of gene editing, iPSC manufacturing, and exosome-based therapies is closing the translational gap faster than any single conventional drug development pathway.
References
- Shin EJ, Choi Y, Jeon EJ, et al. Targeted KEAP1 disruption enhances antioxidant defense and mesenchymal stromal cell therapy for chronic limb-threatening ischemia. Molecular Therapy. 2026;34(7):3949-3961. doi: 10.1016/j.ymthe.2026.03.005 (PMID: 41792998)
- Basu R, Madison MK, Sualeh A, et al. Human induced pluripotent stem cell-derived mesenchymal stromal cells regenerate diabetic ischemic muscle. Bioengineering & Translational Medicine. 2026;11(3):e70119. doi: 10.1002/btm2.70119 (PMID: 42272979)
- Kim DY, Hwang DY, Park G, et al. Adipose-derived dual cell therapy enhances arteriogenesis and limb preservation through vascular integration in critical limb ischemia. npj Regenerative Medicine. 2026;11(1):13. doi: 10.1038/s41536-026-00458-x (PMID: 41593118)
- Du L, Li G, Wan J, et al. hUCB-MSCs secreted exosomal miR-21-5p promotes vascular endothelial tip cell proliferation and migration by downregulating TGF-beta1. Current Stem Cell Research and Therapy. 2026;21(2):136-149. doi: 10.2174/011574888X365920250707101813 (PMID: 40671230)
- Ribeiro M. Advances in cell-based therapies for peripheral arterial disease. Tissue Cell. 2026;101:103417. doi: 10.1016/j.tice.2026.103417 (PMID: 41806630)
- Armstrong DG, Conte MS, Mills JL, et al. Anatomically directed lower extremity gene therapy for ulcer healing: a double-blind, randomized, placebo-controlled study (LEGenD-1). Circulation: Cardiovascular Interventions. 2026;19(1):e015648. doi: 10.1161/CIRCINTERVENTIONS.125.015648 (PMID: 41186002)
- ClinicalTrials.gov identifiers: NCT05854615, NCT05854641, NCT02805023, NCT06813027, NCT06087848